Gold bars to be exempt from tariffs, White House clarifies
NEW YORK - Diaceutics PLC (AIM:LON:DXRX), a technology and solutions provider to the pharmaceutical and biotech industry, announced today that shareholders approved all resolutions at its Annual General Meeting.
The company reported that all 11 proposed resolutions received majority approval from shareholders. These included the receipt of financial statements for the year ended December 31, 2024, approval of the directors’ remuneration report, and re-election of three directors: Cheryl MacDiarmid, Jordan Clark, and Nick Roberts.
Shareholders also approved the re-appointment of Ernst & Young as auditors and authorized directors to determine their remuneration.
Additional approved resolutions included authorizing directors to allot ordinary shares, disapply statutory pre-emption rights, make market purchases of ordinary shares, and approve The Diaceutics Unapproved Share Option Plan.
While most resolutions passed with over 99% support, the directors’ remuneration report received 83.09% approval with 16.91% against, representing the highest opposition among all items voted upon.
The Diaceutics Unapproved Share Option Plan was approved with 93.40% of votes in favor and 6.60% against.
The company made the announcement based on a press release statement issued Wednesday. Diaceutics is listed on London’s AIM market under the ticker DXRX.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.